Overview

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Status:
RECRUITING
Trial end date:
2027-11-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, phase Ib/II study of YL202 in combination with other anti-tumor therapies to Evaluate the Safety, Tolerability, and Efficacy in Patients with Advanced Solid Tumors
Phase:
PHASE1
Details
Lead Sponsor:
MediLink Therapeutics (Suzhou) Co., Ltd.
Treatments:
Injections
toripalimab